In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Which Way Now For Mid-Sized European Pharmas?

Executive Summary

Compared with their top 20 European peers and with similarly sized companies in the US, many mid-sized European pharmas are struggling. IMS Health analyzes the predicament these companies find themselves in and outlines what they need to do to avoid being caught in an evolutionary backwater.

You may also be interested in...



Leo Pharma’s Global Ambitions In Hot Dermatology Space: Assembles New Top Team

The Danish company brings its heads of US, European and international businesses into the top management team to tackle the next stage of its development, targeting patients in new ways in the hot therapy area of dermatology.

Transforming A European Mid-Sized Pharma: An Interview With Almirall President Jorge Gallardo

Spain’s Almirall has taken a step back from the hypercompetitive respiratory market through its deal with AstraZeneca. It was becoming too expensive to compete in primary care against big pharma, says company President Jorge Gallardo. Almirall will use proceeds to chart a future course as a specialty pharma focused on dermatology.

Almirall Eyes Top Specialty Dermatology Role After its AstraZeneca Deal

Spain’s leading pharma company will use proceeds of its respiratory products sale to bulk up in dermatology, with the aim of becoming a global leader in the sector.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1131511

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel